Electronic A	cknowledgement Receipt
EFS ID:	9790294
Application Number:	10566145
International Application Number:	
Confirmation Number:	9831
Title of Invention:	Means and Methods For Treating a Disease Which is Associated With a Excess Transport of Hyaluronan Across a Lipid Bilayer
First Named Inventor/Applicant Name:	Peter Prehm
Customer Number:	33072
Filer:	Paul Lynwood Weaver/Nakole Simon-Liberko
Filer Authorized By:	Paul Lynwood Weaver
Attorney Docket Number:	DFM0004/US (40570-8002)
Receipt Date:	01-APR-2011
Filing Date:	20-DEC-2007
Time Stamp:	13:38:22
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (SB/08)	IPM0004US_Formerly_DFM000 4US_IDS_04_01_11.pdf	129848 04f92c5e3a0ec732b9f9ad6bea94dce4bf09 0688	no	4

Warnings:

Information:

This is not an USPT	O supplied IDS fillable form				
2	Foreign Reference	EP1136552A1.pdf	2380591 3fdf214b8ae6bf727de77e6bf544b7190c5e 4714	no	48
Warnings:					
Information:					
			1226403		
3	Foreign Reference	WO9216226A1.pdf	1220103	no	27
			913c6cbe27 fdc3 8 adeac1fda1 8 34d35bf27f a914		
Warnings:					
Information:					
			901841		
4	Foreign Reference	WO9520385A1.pdf	876e9d09c7b6cbbdc09297707179ec2e4fe	no	19
			ad9e6		
Warnings:					
Information:					
	F : D (NACOCO 40744 16	477213	no	
5	Foreign Reference	WO9603497A1.pdf	6b90f8b9d880d8a2f3e77f0051189d89fd6b		16
Warnings:			d676		
Information:					
information.					
6	Foreign Reference	WO9808538A1.pdf	734533	no	18
	roreignmeterence		1e24dd24a5684fff21c4db222040f6a9a599 7526		10
Warnings:					
Information:					
			3439580		
7	Foreign Reference	WO9848784A2.pdf	3439360	no	67
			884e5e8a67bfc2695a2fd53ec186826711e1 3b40		
Warnings:					
Information:					
			718701		
8	NPL Documents	PCTSearchReportforPCTEP2004 008547.pdf		no	24
		·	e2929f4d270ca7ba176f4e0f120607b372d2 9a2S		
Warnings:					
Information:					
		Moskowitz_Sustained_Release.	994605	no	
9	NPL Documents	pdf pdf	083b2f92ac6c1025dcfbfecfc79b4666ee6c6		11
			e9d		
Warnings:					
Information:					
	NDI D	Maier_etal_Evaluierung.pdf	204951	no	
10	NPL Documents		c62d80c4e13a743724c18fd3a771dd85e0a		4
		d82f4			

Information: 12 NPL Documents Abe_Effect.pdf 335044 no Attraction and application and applica						Warnings:
Marnings:				•		Information:
Marnings:	1	no	115673		NPL Documents	11
12						
12 NPL Documents Abe_Effect.pdf 335044 NPL Documents NPL Documents Woo_etal_Nifedipine.pdf 312317 NPL Documents NPL Documents App_etal_Acute.pdf 740967 NPL Documents NPL Document						Warnings:
NPL Documents Abe_Effect.pdf Abe_E						Information:
Marnings: Information:	6	no	335044	Abe Effect.pdf	NPL Documents	12
13	ĭ					
13						Warnings:
Marnings: Information:						Information:
Warnings:	4	no	312317	Woo etal Nifedinine ndf	NPI Documents	13
Information:		1,10		woo_etal_, wearpine.pu	THE DOCUMENTS	
14						Warnings:
14						Information:
Warnings:			740967	App. atal. Assets add	NDI Dagunaanti	14
Information:	8	no		App_etal_Acute.par	NPL Documents	14
15						Warnings:
15						Information:
Warnings:	10	no	1153146		NPL Documents	15
Information:					The Documents	
16				,		Warnings:
NPL Documents						Information:
Warnings:	8	no	703352		NPI Documents	16
Information: 17 NPL Documents Midtvedt_etal_Nifedipine.pdf 107019 no le52e0c013dde048a0411ecfc4c90314336a bece Warnings: Information: 18 NPL Documents Yang_etal_Effect.pdf 193477 no 6e16fc5eab77b4bd5e908deee6bd4c7b693 c13c5		110		dent.pdf	Ni E Documents	
107019			<u>'</u>			Warnings:
Midtvedt_etal_Nifedipine.pdf						Information:
Te52e0c013dde048a0411ecfc4c90314336a	1		107019	Agida and Alifedia and E	NDI Danimanta	17
Information: 18 NPL Documents Yang_etal_Effect.pdf 193477 6e16fc5eab77b4bd5e908deee6bd4c7b693 c13c5 Warnings:		no			NPL Documents	17
18 NPL Documents Yang_etal_Effect.pdf 193477 For incomplete the second representation of the second re						Warnings:
18 NPL Documents Yang_etal_Effect.pdf no						Information:
18 NPL Documents Yang_etal_Effect.pdf			193477			
Warnings:	2	no	6e16fc5eab77b4bd5e908deee6bd4c7b693	Yang_etal_Effect.pdf	NPL Documents	18
			CISCS			Warnings:
miorination.						Information:
435645			435645	Andersson_etal_Effects.pdf	NDI Decomo	
19 NPL Documents Andersson_etal_Effects.pdf on O178d51d8ddc73252f9fa3cb6bde7117233 d5fc8	6	no			NPL DOCUMENTS	19

Warnings:					
Information:					
20	NPL Documents	Robert_Multidrug.pdf _	634943	no	10
			d504a5038a78387c5092c93c23fdd9f3edc4 c39b		
Warnings:					
Information:					
21	NPL Documents	Laliberte_etal_Tenidap.pdf	1123641	no	12
			942818b48545e5f27c75873c65ad5d502f7 03d5d		
Warnings:					
Information:					
			492568		
22	NPL Documents	Harris_etal_Clinical.pdf		no	10
			e8039639c10b39068f78f9ac6ce5af36ed3e cc33	11	
Warnings:					
Information:					
			275399		
23	NPL Documents	Harris_etal_Effect.pdf	-	no	4
			8557043d7f3fff6b993ccabdac841503c05b 3a38)	
Warnings:					
Information:					
	MEL 5	Broell_etal_Uber_withEnglishTi	196983		4
24	NPL Documents	ans_Discussion.pdf	d048e01118d3a14eb449c473d906e69e31a 83d27	no	
Warnings:			-		
Information:					
25	NICL C	Kanan i lele i i i	201850		
25	NPL Documents	Kagan_etal_Flufenamic.pdf	53dbf0a2a654c87af19fc4e26262db09634b 08ee	no no	4
Warnings:					
Information:					
26	ND D	Appelboom_etal_Proglumetaci	360831		8
26	NPL Documents	n.pdf	77bbafbf0ddc179901891ed80008c69f5bb 0095d	no	
Warnings:			,		
Information:					
			142460		
27	NPL Documents	Jorgensen_etal_Multidrug.pdf		no	4
			04f1adde078269806c672ef5a8960e007161 6d32		
		•			
Warnings:					
Warnings: Information:	NPL Documents	Salmon_etal_Relevance.pdf	313988		6

Warnings:	
Information:	
Total Files Size (in bytes):	19047569

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.